Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2007

View Archived Issues

Phase I/II study of Oncohist in leukemia progresses

Activity seen with SNS-595 in acute leukemia patients

Preliminary phase I results with AT-9283 in hematological malignancies encouraging

Bupropion ameliorates methamphetamine dependence in some patients

New agents for musculoskeletal and connective tissue disorders claimed in recent patents

Novel therapeutic agents for Alzheimer's disease disclosed in recent patent literature

Update on Intra-Cellular Therapies' ITI-007/ITI-722 for schizophrenia and SMI

New agents for treating hematologic disorders reported in recent patents

Tissue-specific FAK gene deletion blocks mammary tumor progression

Ono enters license agreement with Nissan Chemical for new drug for thrombocytopenia

Novavax reports positive interim results from phase I/IIa trial of H5N1 vaccine

Nektar and Baxter expand agreement to develop PEGylated therapeutics for hemophilia

CFFT selects Triolex as drug candidate for lung inflammation linked with cystic fibrosis

Intercell submits BLA with FDA for Japanese encephalitis virus vaccine

Phase III clinical trial of Genitope's MyVax fails to meet primary endpoint

Peregrine gives update on its three lead clinical programs for bavituximab and Cotara

Actelion initiates RESTORA 1 phase III study of almorexant for primary insomnia

Corcept commences phase III Corlux trial for endogenous Cushing's syndrome

Pfizer receives FDA approvable letter for dalbavancin

GlaxoSmithKline and Santaris enter RNA antagonist alliance

Taxus Liberte drug-eluting stent receives CE mark for use in patients with diabetes

GlobeImmune initiates phase II GI-5005 trial in patients with chronic hepatitis C

ExonHit obtains approval to start phase II EHT-0202 trial in Alzheimer's disease

Galapagos enters strategic alliances with GlaxoSmithKline and Lilly

R-1507 antibody enters phase II sarcoma study

Phase II IPI-504 trial initiated in patients with non-small cell lung cancer

Conatus initiates phase II clinical trial for the treatment of hepatitis

VGX files IND for VGX-1027, a small molecule with antiinflammatory activity

Bazedoxifene receives second FDA approvable letter for prevention of osteoporosis

Noven reports FDA tentative approval of Stavzor valproic acid delayed release capsules

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...